Pioneering the Future of Nephrotic Syndrome Research with ARREST-NEPHROSIS
Nephrotic Syndrome affects millions globally, presenting a significant health burden with its hallmark symptoms of severe proteinuria and edema. The quest for advanced treatments underscores the crucial role of biobanks and registries, which are instrumental in propelling medical research and innovation. At the forefront of this effort is ARREST-NEPHROSIS, an Austrian registry that exemplifies how […]
What to Expect From The Pharmaceutical Industry In 2024
As we step into 2024, the pharmaceutical industry stands at the cusp of remarkable advancements and significant transformations. This year promises to be a pivotal one, with key trends, innovations, and challenges shaping the future of healthcare and medicine and defining the pharmaceutical landscape. Key Pharmaceutical Industry Trends to Watch in 2024 Let’s explore the […]
Digital Health Envision Summit
We are delighted to announce that Dr. Klaus Kratochwill, CSO, and Dr. Paul Perco, Computational Biology Lead of Delta4, are looking forward to attending the prestigious 2023 Digital Health Envision Summit to be held in London, UK. The summit, renowned for being a hub of innovation in healthcare and neurology, aligns seamlessly with Delta4’s mission […]
Delta4 at RExPO: Pushing the Boundaries of Drug Repurposing
We are thrilled to announce that Delta4 will be in attendance at this year’s RExPO23, a landmark event in the realm of Systems Medicine, Artificial Intelligence, and Drug Repurposing. As pioneers in AI-enabled drug repurposing and indication expansion, our presence underscores our commitment to fostering global collaborations and accelerating advancements in this transformative field. Dr. […]
Reactome Spotlights Delta4’s Computational Drug Repositioning of Clopidogrel for FSGS
We are honored to announce that our publication on the computational drug repositioning of clopidogrel has been highlighted in the Reactome research spotlight. This notable recognition from a reputable bioinformatics database underscores the potential of our innovative approach in addressing Focal Segmental Glomerulosclerosis (FSGS), a severe glomerular lesion associated with nephrotic syndrome and a high […]
Delta4’s Innovation Shines: OntoloViz Article Published in Bioinformatics Advances Journal
We are thrilled to announce that our journal article, titled “OntoloViz: a GUI for interactive visualization of ranked disease or drug lists using the MeSH and ATC ontologies,” has been published in the esteemed Bioinformatics Advances Journal. This publication accentuates Delta4’s continuous endeavor to push the boundaries of TechBio innovation, bridging computational power and biological […]
Drug Indication Expansion: Unlocking Untapped Potential
In the vast ecosystem of the pharmaceutical industry, drug indication expansion plays a pivotal role in maximizing the potential of existing drugs. This critical aspect of health and medicine enables companies to provide more treatments for patients, while potentially increasing revenue. What is Drug Indication Expansion? Drug indication expansion refers to the approval of existing […]
Advancing Healthcare Through Drug Discovery Services: Unleashing the Power of Innovation
In the realm of healthcare, the journey from a promising drug idea to an effective therapy is not a straightforward one. The process of drug discovery is highly complex and generally takes years from the initial idea to – in an ideal scenario – the final approval. It requires experts from different fields, therefore making […]
What is Drug Discovery? Unveiling the Process, Challenges, and Future
In the intricate world of healthcare, the journey of a drug from a basic idea to a therapy that can change lives is a challenging one. This process, known as drug discovery, is a rigorous, meticulous, and elaborate journey that requires a high level of expertise in various fields such as biology, chemistry, computer science, […]
Delta4 Identifies a Potential New Therapeutic Option for Focal Segmental Glomerulosclerosis (FSGS) using computational Hyper-C Drug Discovery Platform
Delta4, a digital drug discovery company, identified a potential therapeutic option for Focal Segmental Glomerulosclerosis (FSGS) using their Hyper-C AI software platform. The anti-platelet drug clopidogrel was among the top predictions and was shown to alleviate disease progression in an accepted FSGS animal model, suggesting it is a promising candidate for clinical trials. May 24, […]